New pages
Jump to navigation
Jump to search
- 02:46, 21 June 2024 Rytelo (hist | edit) [10,735 bytes] Kosar Doraghi (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag=Kosar Doraghi, M.D. [mailto:K.doraghi@yahoo.com] |genericName=Imetelstat |aOrAn=an |drugClass=oligonucleotide telomerase inhibitor |indicationType=treatment |indication=oligonucleotide telomerase inhibitor adult patients with low- to intermediate-1 risk myelodysplastic syndromes (MDS) with transfusion-dependent anemia requiring 4 or more red blood cell units over 8 weeks who have not responded to or have lost response to or are...")
- 02:37, 19 June 2024 TATA box human genes (hist | edit) [168,041 bytes] Marshallsumter (talk | contribs) (Created page with "The '''TATA box''' (also called '''Goldberg-Hogness box''')<ref name=Lifton>{{ cite journal | author = R. P. Lifton, M. L. Goldberg, R. W. Karp, and D. S. Hogness | year = 1978 | title = The organization of the histone genes in Drosophila melanogaster: functional and evolutionary implications | url = https://symposium.cshlp.org/content/42/1047.extract | journal = Cold Spring Harbor Symposia on Quantitative Biology | volume = 42 | issue = | pages = 1047–51 | doi = 10.11...")
- 23:02, 8 June 2024 Xolremdi (hist | edit) [15,658 bytes] Kosar Doraghi (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag=Kosar Doraghi, M.D. [mailto:k.doraghi@yahoo.com] |genericName=mavorixafor |aOrAn=a |drugClass=CXC chemokine receptor 4 (CXCR4) antagonist |indicationType=treatment |indication=patients 12 years of age and older with WHIM syndrome (warts, hypogammaglobulinemia, infections and myelokathexis) to increase the number of circulating mature neutrophils and lymphocytes. |hasBlackBoxWarning=Yes |adverseReactions=thrombocytopenia, pityr...")
- 23:19, 2 June 2024 Iptacopa (hist | edit) [11,398 bytes] Rithish Nimmagadda (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{VSRN}} |genericName=iptacopa |aOrAn=a |drugClass=complement factor B inhibitor. |indicationType=treatment |indication=adults with paroxysmal nocturnal hemoglobinuria (PNH). |hasBlackBoxWarning=Yes |adverseReactions=Most common adverse reactions in adults with PNH (incidence ≥10%) were headache, nasopharyngitis, diarrhea, abdominal pain, bacterial infection, viral infection, nausea, and rash. |blackBoxWarningTitle=Serious Infecti...")
- 03:20, 1 June 2024 WINREVAIR (hist | edit) [17,147 bytes] Kosar Doraghi (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag=Kosar Doraghi, M.D. [mailto:k.doraghi@yahoo.com] |genericName=sotatercept-csrk |aOrAn=an |drugClass=activin signaling inhibitor |indicationType=treatment |indication=adults with pulmonary arterial hypertension (PAH, WHO Group 1) to increase exercise capacity, improve WHO functional class (FC) and reduce the risk of clinical worsening events |hasBlackBoxWarning=Yes |adverseReactions=headache, epistaxis, rash, telangiect...")
- 23:42, 27 May 2024 Evinacumab-dgnb (hist | edit) [627 bytes] Jonathan Reyes (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{JR}} |genericName=evinacumab-dgnb |aOrAn=an |drugClass=angiopoietin-like 3 (ANGPTL3) inhibitor |indicationType=treatment |indication=Evanicumab-dgnb is an angiopoietin-like 3 (ANGPTL3) inhibitor that is FDA approved for the treatment of an adjunct to other low-density lipoproteincholesterol (LDL-C) lowering therapies for the treatment of adult and pediatric patients, aged 5 years and older, with homozygous familial hypercholestero...")
- 14:40, 23 May 2024 Glofitamab-gxbm (hist | edit) [8,803 bytes] Muhammad Waleed (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag=Muhammad Waleed, M.B.B.S. [mailto:muhammad_waleed@ymail.com] |genericName=glofitamab. |aOrAn=a |drugClass=bispecific antibodies |indicationType=treatment |indication=COLUMVI (glofitamab) has been approved by the FDA for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS), or large B-cell lymphoma arising from follicular lymphoma aft...")
- 12:43, 23 May 2024 Rozanolixizumab-noli (hist | edit) [8,759 bytes] Muhammad Waleed (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag=Muhammad Waleed, M.B.B.S. [mailto:muhammad_waleed@ymail.com] |genericName=Rozanolixizumab-noli (Rystiggo) |aOrAn=a |drugClass=Neonatal Fc receptor blocker |indicationType=treatment |indication=Rystiggo is indicated for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive. |adverseReac...")